Nutriband Inc. (NTRB) 주식 분석

회사 개요

Nutriband Inc. (NTRB) is a biotechnology enterprise focused on developing a portfolio of transdermal pharmaceutical products within the United States, with its primary asset currently being AVERSA fentanyl, an abuse-deterrent transdermal system designed to offer extended-release fentanyl delivery for clinicians and patients. The company operates within the broader Healthcare sector, specifically specializing in the Biotechnology industry, where innovation in drug delivery mechanisms and regulatory compliance are critical for market entry and commercialization. As of the latest reporting period, the company holds a market capitalization of $48.70M, though specific data regarding the annual number of employees is not disclosed in available records. These valuation and revenue metrics, combined with the absence of disclosed headcount figures, indicate that Nutriband Inc. is a small-cap entity operating in a high-risk, high-reward developmental stage typical of early-stage biotech firms that have not yet achieved significant commercial scale or profitability. The market cap of $48.70M reflects the market's assessment of the company's potential based on its pipeline assets rather than current cash flows, while the lack of revenue scale relative to the biotechnology sector suggests the company is still in the phase of product development or limited commercialization.

재무 건전성

Nutriband Inc. reported a trailing twelve-month revenue of $2.28M, yet this revenue figure is accompanied by a net income loss of $-34,592,176, revealing a cost structure where expenses significantly outweigh income generation. The EBITDA for the period stands at $-9,029,840, further highlighting the substantial operational costs associated with research, development, and administrative functions that have not yet been offset by commercial sales. The company generated free cash flow of $-2,588,350, indicating a consumption of cash reserves that limits immediate financial flexibility for expansion or acquisitions without external capital infusion. Profitability analysis shows a gross margin of 33.5%, suggesting that the cost of goods sold for its transdermal products is controlled, but this positive gross margin is heavily eroded by operating expenses, resulting in an operating margin of -1121.3% and a profit margin of 0.0%. The balance sheet liquidity is assessed by comparing total cash of $5.31M against total debt of $258,025, resulting in a debt-to-equity ratio of 3.42, which indicates a leveraged position where equity is heavily diluted relative to debt obligations despite the absolute dollar amount of debt being relatively low. Short-term liquidity appears robust given a current ratio of 7.53, suggesting the company possesses ample current assets to cover its short-term liabilities. However, the return metrics are severely impacted by the financial losses, with a return on equity of -136.1% and a return on assets of -55.2%, which reveal that management effectiveness in generating value for shareholders and utilizing asset bases is currently negative due to ongoing operational deficits.

밸류에이션 평가

The valuation metrics for Nutriband Inc. present a unique picture due to its lack of earnings, as the trailing P/E ratio is N/A and the forward P/E is listed as -17.39, implying that the market is pricing the stock based on non-traditional multiples or future expectations rather than historical profitability. The price-to-book ratio is 6.44, indicating that the market values the company at a significant premium over its net book value, a common characteristic for biotech firms where intellectual property and pipeline potential are valued higher than tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 21.38 and an EV/EBITDA of -4.83 suggest that the stock is priced based on revenue potential and enterprise value relative to earnings before interest, taxes, depreciation, and amortization, rather than current earnings power. The stock's trading range over the last 52 weeks spans from a low of $3.42 to a high of $11.68, and while the exact current price is not listed in the provided facts, the wide range indicates significant volatility and sensitivity to biotech sector sentiment. The beta value of 1.93 signifies that the stock's price volatility is substantially higher than the broader market, meaning it is expected to experience larger swings in both directions compared to the overall market index.

Growth & Income

Nutriband Inc. experienced a revenue growth rate of -46.4% year-over-year, while earnings growth is N/A due to the company's negative earnings position, implying that the company is facing contraction in revenue rather than expansion during this period. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that any generated cash or potential future earnings are not distributed to shareholders but are instead retained within the company to fund operations and development efforts. Consequently, the company reinvests its limited financial resources into its transdermal pharmaceutical portfolio rather than providing income to investors, a strategy typical for early-stage biotechnology companies that prioritize capital allocation toward research and development over shareholder returns. The overall growth and income profile is characterized by negative revenue momentum and a complete absence of dividend income, reflecting the company's status as a capital-intensive development entity seeking to transition from product development to commercial profitability to alter its financial trajectory.